Biovica International AB (publ) (BIOVIC-B.ST)
Stockholm · SEK · Healthcare · Biotechnology
SEK 0.326 (+3.16%) as of
Key statistics
- Market cap
- 126.88M
- Forward P/E
- -0.31
- EPS (TTM)
- -0.2600
- Dividend yield
- 0.00%
- 52-week range
- 0.2700 – 0.6100
- Beta
- 1.22
- Revenue (TTM)
- 14.93M
- Profit margin
- 0.00%
- Analyst target
- SEK 0.60
- Volume
- 515.48k
About Biovica International AB (publ)
Biovica International AB (publ), a biotech company, develops and commercializes blood-based biomarker assays for oncologists monitor cancer progression in the European Union, the United States, and Asia. The company engages in the development of DiviTum TKa, a monitoring tool for patients with early or metastatic breast cancer undergoing treatment with CDK4/6 inhibitors. It serves cancer institutes and pharmaceutical companies. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Uppsala, Sweden
- Employees
- 24
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.